ASG's Xiaoqing Boynton spoke with the South China Morning Post about China's plans to export hundreds of millions of doses of Covid-19 vaccine around the world. Read the full article here.

But navigating between overseas commitments and domestic needs will be a “balancing act” that Beijing needs to manage well, according to Xiaoqing Boynton, a vice-president at Washington consultancy Albright Stonebridge Group.

“China doesn’t currently have an active outbreak, so in terms of prioritisation you have a domestic agenda, however you are also dealing with very active hotspots globally, including localities that are of strategic importance to China,” said Boynton, who focuses on China’s health and life science sectors.

...

Albright Stonebridge Group’s Boynton said “transparency is the key” to building up the level of public trust and confidence in China’s vaccines, not least of all because China’s vaccine industry had faced safety scandals in recent years.

But there has also been substantial investment from China to position itself as a contributor to Covid-19 vaccination internationally, she said.

“This is a unique opportunity for Chinese industry to demonstrate its qualifications, in terms of safety and quality standards, and become a reliable supplier of vaccines on a global scale,” Boynton said.